Berlin - Delayed Quote EUR

AcelRx Pharmaceuticals Inc (R5XA.BE)

0.4560

-0.0050

(-1.08%)

At close: May 14 at 9:40:06 PM GMT+2

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.

PR Newswire 4 hours ago

TLPH
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.

PR Newswire 7 days ago

TLPH
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights

Talphera Inc (TLPH) secures significant investment and FDA approvals, while navigating challenges in clinical trials and financial milestones.

GuruFocus.com last month

TLPH
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.

PR Newswire last month

TLPH
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously included in the study protocol. The Company also announced it has entered into securities purchase agreements with certain institutional investors and a member of management for the

PR Newswire last month

TLPH
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.

PR Newswire last month

TLPH
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), the agency has agreed to review a Prior Approval Supplement (PAS) requesting a reduction in the number of patients in the NEPHRO CRRT clinical study. A PAS is reviewed by the FDA within 30 days, and its approval by

PR Newswire 3 months ago

TLPH
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024.

PR Newswire 5 months ago

TLPH

ASPHF

OLMA
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)

Talphera ( NASDAQ:TLPH ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.35m (loss widened by 137% from...

Simply Wall St. 5 months ago

TLPH
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

Talphera Inc (TLPH) reports progress in clinical trials and regulatory pathways, while addressing enrollment hurdles and financial needs.

GuruFocus.com 5 months ago

TLPH
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.

PR Newswire 5 months ago

TLPH
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.

PR Newswire 6 months ago

TLPH
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.

PR Newswire 7 months ago

TLPH
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.

PR Newswire 8 months ago

TLPH
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.

PR Newswire 8 months ago

TLPH
Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023)

Talphera ( NASDAQ:TLPH ) First Half 2024 Results Key Financial Results Net loss: US$7.78m (loss widened by 78% from 1H...

Simply Wall St. 8 months ago

TLPH
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update.

PR Newswire 8 months ago

TLPH
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in conn

PR Newswire 11 months ago

TLPH
Talphera to Participate at A.G.P. Virtual Healthcare Conference

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.

PR Newswire 11 months ago

TLPH

Performance Overview

Return	R5XA.BE	S&P 500 (^GSPC)
YTD	-10.76%	+0.19%
1-Year	-51.59%	+12.31%
3-Year	-88.66%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AcelRx Pharmaceuticals Inc (R5XA.BE)

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)

Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023)

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Performance Overview